CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia

PHASE2RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

January 18, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

B-cell Acute Lymphoblastic LeukemiaB-cell LymphomaDiffuse Large B Cell Lymphoma

Interventions

DRUG

CD19/CD22-bispecific CAR-T cells

CD19/CD22-bispecific CAR-T cells were infused at the same day with 2×10e6/kg and 1×10e6/kg dosage, respectively.

Trial Locations (1)

RECRUITING

Liang Wang, Beijing

All Listed Sponsors

lead

Beijing Tongren Hospital

OTHER